Previous 10 | Next 10 |
KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q4 GAAP EPS of -$0.98 beats by $0.11 . Cash, cash equivalents and marketable securities were $166.2M on April 30, 2022, compared to $248.9M on April 30, 2021. The decrease in the net cash position over the fiscal ...
– Sebetralstat data examines efficacy by attack location and population PK comparisons – – Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a cli...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 European Academy of Allergy a...
– First preclinical data presented for structurally diverse oral Factor XIIa inhibitors - – Additional Sebetralstat data also presented - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, de...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 13 th Annual Jefferies Global Healthcare Conf...
– “Sebetralstat” Approved by WHO and USAN – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today anno...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 21 st Annual Needham Virtual Healthcare Confe...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new data in Clinical & Experimental Allergy charact...
KalVista Pharmaceticals press release (NASDAQ:KALV): Q3 GAAP EPS of -$0.92 in-line. Cash, cash equivalents and marketable securities were $194.8 million as of January 31, 2022, compared to $248.9 million as of April 30, 2021. For further details see: KalVista Pharmaceticals GAAP E...
KalVista Pharmaceuticals (NASDAQ:KALV) began a phase 3 trial, dubbed KONFIDENT, evaluating its potential oral drug KVD900 for hereditary angioedema (HAE) attacks. HAE is a disorder characterized by recurrent attacks of severe swelling of the skin and mucous membranes. The company sa...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...